Biogenically derived silica nanoparticles may serve as a well-defined target vehicle for drug delivery and have a wide range of applications in biomedicine. Silica nanoparticles are an excellent candidate as drug carriers due to their mesoporous structure, high drug loading capacity, low toxicity, environmental friendliness and low economic synthesis procedures. In this study, nano structured silica was extracted from sugarcane bagasse through an alkali leaching extraction and conjugated with A. muricata extract overcoming its poor solubility and improving its bioavailability within the host system. The Silica Nanoparticles (SNP) and Annona muricata conjugated Silica Nanoparticles (AM/SNP) were characterized using SEM, FTIR, TGA, EDAX, XRD and zeta potential. The AM/SNP was subjected to kinetic release studies and exhibited a sustained release of 64 % over the course of 12 h in contrast to extract, indicating the slow release of the drug under synthetic conditions. A. muricata pose a high affinity against tumor cells as an anti-cancer agent, and the potential of binding was testified using in-silico virtual screening against breast cancer receptors with lead acetogenins with Annomuricin (-7.4 kcal/mol) and Gigantecin (-7.4 kcal/mol) exhibiting a high binding affinity against ER and HER2+ receptors respectively. The AM/SNP conjugate exhibited high cytotoxicity against the MCF-7 breast cancer cell line with an IC50 value of 33.43 μg, indicating high potency of the conjugate at low concentrations, facilitating low systemic toxicity on administration.
Keywords: Annona muricata; Biogenic synthesis; Breast cancer; Cell line studies; Silica nanoparticles; Silica/Annona muricata nano-hybrids.
© 2024 Published by Elsevier Ltd.